BIOMARIN PHARMACEUTICAL INC - 8-K Filing
BioMarin settles patent dispute with Ascendis, securing royalties on Yuviwel sales in the U.S., EU, Brazil, and South Korea until May 2030. (Items: 1.01 Entry into a Material Definitive Agreement, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $BMRN